Scientists have carried out one of the most comprehensive studies into how immune cells sense and respond to their environment to fight infection and destroy tumors.
The research team published their findings in the journal Nature Immunology, said the results provide important insights into how immune responses might be manipulated for the treatment of autoimmune diseases and cancer.
The study was focused on T lymphocytes, a population of white blood cells essential for immune responses to cancer, bacteria and viruses, and transplanted organs.
They mapped how these cells control expression of more than 9,000 proteins as they take part in immune responses. They also mapped in fine detail how an important immune-suppressive drug, used to prevent organ rejection in transplants, selectively controls these processes.
The authors reveal that lymphocyte environment sensing is controlled by immune activation, and that CD4+ and CD8+ T cells differ in their intrinsic nutrient transport and biosynthetic capacity.
They also reveal shared and divergent outcomes of mTORC1 inhibition in naïve versus effector T cells: mTORC1 inhibition impaired cell cycle progression in activated naïve cells, but not effector cells, whereas metabolism was consistently impacted in both populations.
One of the senior authors said, "These results have implications for our understanding of how harmful or beneficial immune responses can be manipulated for better health outcomes in organ transplantation and cancer.
"A critical discovery is that exposure to foreign stimuli, such as viruses and bacteria, make T lymphocytes switch on expression of key sensors for oxygen and nutrients and also make T lymphocytes switch on expression of transporters that allow cells to import nutrients from their environment.
"Drugs used to block immune responses work by controlling these key metabolic pathways."
The study also shows how the ability of immune cells to mount effective responses can be shaped by the oxygen and nutrient environment the cells work in.
The research team explored how T cells re-program expression of thousands of cellular proteins in response to stimulation and provided a comprehensive understanding of how immune-suppressive drugs control T lymphocyte behavior.
https://www.dundee.ac.uk/news/2019/from-sleeping-cell-to-assassin--how-immune-cells-work.php
https://www.nature.com/articles/s41590-019-0495-x
Proteomics of T cell differentiation!
- 712 views
- Added
Edited
Latest News
Zone 2 hepatocytes help in maintenance and regeneration of liver
Nanobody-mediated control of gene expression and epigenetic memory
Re-engineering Botox for Multiple Functions
New signaling pathway in neurons
Mother's diet boosts immune systems of premature infants
Other Top Stories
Increased Susceptibility of Females to Depression is Linked to Long Non-coding RNAs
Molecular effects of exercise
Stopping drug cravings with fewer side effects
Automated flow synthesis of proteins in the lab
Mechanism of action of anesthesia on consciousness solved!
Protocols
Dual-Angle Protocol for Doppler Optical Coherence Tomography to Improve Retinal Blood Flow Measur…
Detection of protein SUMOylation in vivo
In vivo analysis of protein sumoylation induced by a viral protein: Detection of HCMV pp71-induce…
Determination of SUMOylation sites
miR-Selection 3'UTR Target Selection Kit
Publications
Nanobody-mediated control of gene expression and epigenetic memory
Interaction of 7SK with the Smn complex modulates snRNP production
Maternal aryl hydrocarbon receptor activation protects newborns against necrotizing enterocolitis
Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum
Neurobiology of bipolar disorders: a review of genetic components, signaling pathways, biochemica…
Presentations
Liver Cirrhosis
Botulinum toxin
Bioplar Disorder
G-Protein-Coupled Receptors
Mood Disorders
Posters
ASCO-2020-CENTRAL NERVOUS SYSTEM TUMORS
ASCO-2020-DEVELOPMENTAL THERAPEUTICS–IMMUNOTHERAPY
ASCO-2020-DEVELOPMENTAL THERAPEUTICS–MOLECULARLY TARGETED AGENTS AND TUMOR BIOLOGY
ASCO-2020-CANCER PREVENTION, RISK REDUCTION, AND GENETICS
ASCO-2020-BREAST CANCER–METASTATIC